文献速递生殖医学

辅助生殖技术中使用来曲唑不增加重大先天畸形或不良妊娠或新生儿结局风险

No increased risk of major congenital anomalies or adverse pregnancy or neonatal outcomes following letrozole use in assisted reproductive technology.
PubMed 文献 · Hum Reprod · 2016-11-07

这项回顾性队列研究利用2011至2013年日本全国辅助生殖技术登记数据,分析3136个自然周期和792个来曲唑诱导周期的新鲜单胚胎移植临床妊娠。来曲唑组流产风险显著降低(aOR 0.37,95%CI 0.30-0.47,P<0.001),重大先天畸形风险无显著差异(自然周期1.5% vs 来曲唑1.9%,aOR 1.24,95%CI 0.64-2.40,P=0.52),其他妊娠和新生儿结局两组相当。

要点

  • 来曲唑组流产风险显著低于自然周期组(aOR 0.37,95%CI 0.30-0.47,P<0.001)。
  • 重大先天畸形总体风险两组无显著差异(自然周期1.5% vs 来曲唑1.9%,aOR 1.24,95%CI 0.64-2.40,P=0.52)。
  • 其他妊娠和新生儿结局两组相当,亚组分析未显示特定器官系统风险增加。

核心结论

  • 与自然周期相比,来曲唑显著降低流产风险,且不增加重大先天畸形或不良妊娠或新生儿结局风险。

研究设计与样本

  • 回顾性队列研究,使用2011至2013年日本全国辅助生殖技术登记数据,纳入3136个自然周期和792个来曲唑诱导周期的新鲜单胚胎移植临床妊娠。

主要发现

  • 流产风险来曲唑组显著低于自然周期组(aOR 0.37,95%CI 0.30-0.47,P<0.001)。
  • 重大先天畸形总体风险两组无显著差异(自然周期1.5% vs 来曲唑1.9%,aOR 1.24,95%CI 0.64-2.40,P=0.52),且无特定器官系统风险增加。
  • 亚组分析显示,体外受精或卵胞浆内单精子注射患者,以及早期卵裂期或囊胚期胚胎移植患者,重大先天畸形风险均未增加。
  • 其他所有妊娠和新生儿结局两组相当。

临床怎么用

  • 作者认为,来曲唑可能是轻度卵巢刺激的安全选择。

局限性

  • 尽管样本量大,本研究仅能排除来曲唑在辅助生殖技术患者中导致出生缺陷风险大幅增加的可能性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does letrozole use increase the risk of major congenital anomalies and adverse pregnancy and neonatal outcomes in fresh, single-embryo transfer? SUMMARY ANSWER: Letrozole significantly decreases the risk of miscarriage and does not increase the risk of major congenital anomalies or adverse pregnancy or neonatal outcomes compared with natural cycles in patients undergoing ART. WHAT IS KNOWN ALREADY: Letrozole is the most commonly used aromatase inhibitor for mild ovarian stimulation in ART. However, its safety in terms of pregnancy and neonatal outcomes is unclear. STUDY DESIGN SIZE, DURATION: This retrospective cohort study used data from the Japanese national ART registry from 2011 to 2013. PARTICIPANTS/MATERIALS, SETTING, METHODS: A total of 3136 natural cycles and 792 letrozole-induced cycles associated with fresh, single-embryo transfer and resulting in a clinical pregnancy were included in the analysis. The main pregnancy outcomes were miscarriage, ectopic pregnancy and still birth, and the neonatal outcomes were preterm delivery, low birth weight, small/large for gestational age and major congenital anomalies. Terminated pregnancies were included in the analysis of major congenital anomalies. Odds ratios (ORs) and 95% CIs were calculated using multivariate logistic regression analysis adjusted for maternal age and calendar year. MAIN RESULTS AND THE ROLE OF CHANCE: The risk of miscarriage was significantly lower in women administered letrozole (adjusted OR [aOR], 0.37, 95% CI, 0.30-0.47, P < 0.001). There was no significant difference in the overall risk of major congenital anomalies between the two groups (natural cycle 1.5% vs letrozole 1.9%, aOR, 1.24, 95% CI, 0.64-2.40, P = 0.52), and no increased risk for any specific organ system. Subgroup analysis demonstrated that the risk of major congenital anomalies was not increased in patients who underwent either in vitro fertilization or ICSI, or in those who received early cleavage stage or blastocyst embryo transfer. All other pregnancy and neonatal outcomes were comparable between the two groups. LIMITATIONS REASONS FOR CAUTION: Despite the large sample size, we were only able to rule out the possibility that letrozole might cause large increases in birth-defect risks in ART patients. WIDER IMPLICATIONS OF THE FINDINGS: The results suggest that letrozole stimulation reduces the risk of miscarriage, with no increase in the risk of major congenital anomalies or adverse pregnancy or neonatal outcomes compared with natural cycles in women undergoing ART. Letrozole may thus be a safe option for mild ovarian stimulation. STUDY FUNDING/COMPETING INTERESTS: None. TRIAL REGISTRATION NUMBER: Not applicable.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Tatsumi T, Jwa SC, Kuwahara A, et al. No increased risk of major congenital anomalies or adverse pregnancy or neonatal outcomes following letrozole use in assisted reproductive technology. Hum Reprod. 2016. PMID: 27821708

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。